Development. Validation. Accessibility.
Helping to Improve Patient Outcomes through Liquid BiopsyOur Community
Driving Innovation in Liquid Biopsy to Advance Cancer Care
The Blood Profiling Atlas in Cancer (BLOODPAC) Consortium was launched on October 17, 2016 to accelerate the development, validation and clinical use of liquid biopsy assays to better inform medical decisions and improve patient care and outcomes. With input from regulatory, industry, and academic institution members, the BLOODPAC Consortium established that many of the challenges in the broader field of liquid biopsy resulted from a lack of collaboration, not any limitations of technology platforms or stalled science.
From Our Socials
-
We’re gearing up for our Annual New Frontiers Seminar!
At our Q3 meeting, Asaf Zviran shared exciting updates on this year’s program. The 2025 seminar will dive into multimodal data and its integration into liquid biopsy for therapy selection, with an outstanding lineup of speakers and panelists already confirmed.
Join us this fall for what promises to be a dynamic and insightful discussion.
👉 Register here.
👉 And you can check last year’s seminar here.View the post here.
-
Exciting update from BLOODPAC!
The Global Regulatory Working Group’s article, “BLOODPAC's Collaborations with European Union Liquid Biopsy Initiatives,” has just been published in the Journal of Liquid Biopsy.
A special thanks to the co-chairs of the group, Elaine Katrivanos and Jennifer Dickey, who led this effort, and to all of our working group members whose dedication made this paper possible.
The piece highlights key challenges and offers solutions to help expand patient access to liquid biopsy technologies worldwide.
Building on this momentum, the Global Regulatory Working Group will host a dinner in Berlin this October, alongside ESMO Congress 2025, to further discussions on advancing global regulatory initiatives and strengthening collaborations across the EU.
Read the article here.View the post here.
-
We had a fantastic Q3 meeting in Madison, WI! 🫶
A big thank you to Exact Sciences for hosting us, and to our members for driving progress through full days of impactful discussions and collaboration. The progress made in our working groups is paving the way for the future of liquid biopsy.
On to what’s next!View the post here.
How We Work
EVIDENCE GENERATION
Align around a framework for evidence generation to bring liquid biopsy into routine clinical practice.
BLOODPAC PORTAL
Enables community storing, sharing and analysis of liquid biopsy datasets for the community.
STAKEHOLDER ENGAGEMENT
Accelerate approval through stakeholder engagement.
“Cancer knows no borders, and neither should innovative technologies that can improve people's lives. BLOODPAC's work to foster a global dialogue on regulatory standards will help accelerate the process of bringing liquid biopsy to clinical settings around the world for patient benefit.”
JENNIFER DICKEY
Head, Regulatory and Quality at Personal Genome Diagnostics
